Premium functions are now FREE OF CHARGE due to the modification of the investment data Data developments may cause some parts work incorrectly Incorrect sections - Financial statements, Earnings upcoming dates and calendars Please take our apologise. It will be fixed soon

ROIV - Roivant Sciences Ltd


IEX Last Trade
12.23
0.210   1.717%

Share volume: 4,975,512
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$12.02
0.21
1.75%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
24%
Profitability 29%
Dept financing 10%
Liquidity 75%
Performance 10%
Company vs Stock growth
vs
Performance
5 Days
2.95%
1 Month
14.62%
3 Months
17.71%
6 Months
4.44%
1 Year
5.61%
2 Year
249.43%
Key data
Stock price
$12.23
P/E Ratio 
1.91
DAY RANGE
N/A - N/A
EPS 
$5.66
52 WEEK RANGE
$8.24 - $13.24
52 WEEK CHANGE
$0.05
MARKET CAP 
9.044 B
YIELD 
N/A
SHARES OUTSTANDING 
739.522 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
0.96
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,456,222
AVERAGE 30 VOLUME 
$4,144,041
Company detail
CEO: Matthew Gline
Region: US
Website: http://roivant.com/
Employees: 309
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

roivant is a global healthcare company focused on rapidly developing innovative medicines. we believe that the key to unlocking innovation in drug discovery and drug commercialization is to reduce the time and cost of the drug development process. we solve this problem by building vants – nimble, entrepreneurial biotech companies with a unique approach to sourcing talent, aligning economic incentives, and deploying technology to drive greater efficiency in pharma r&d; and commercialization. the goal of our model is to ensure that important medicines rapidly reach patients who suffer from serious diseases. we focus on disease areas where the magnitude of r&d; investment from industry is disproportionately low relative to societal medical needs. we also launch new vants to directly improve the process of developing and commercializing new medicines. our pipeline spans multiple therapeutic areas through partnerships with academic institutions and biopharmaceutical companies, including tak

Recent news